Literature DB >> 24478449

Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.

Ian Morrissey1, Samuel K Bouchillon2, Meredith Hackel2, Douglas J Biedenbach2, Stephen Hawser1, Daryl Hoban2, Robert E Badal2.   

Abstract

A subset of Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates collected for the Study for Monitoring Antimicrobial Resistance Trends that were positive for the Clinical and Laboratory Standards Institute (CLSI) extended-spectrum β-lactamase (ESBL) phenotypic confirmatory test (n = 3245) or had an ertapenem MIC of ≥0.5 µg ml(-1) (n = 293), or both (n = 467), were analysed for ESBL genes. Most ESBL phenotype E. coli or K. pneumoniae possessed an ESBL gene (95.8 and 88.4 %, respectively), and this was 93.1 % if carbapenem-non-susceptible K. pneumoniae were removed. This rate was lower for P. mirabilis (73.4 %) and K. oxytoca (62.5 %). Virtually all ESBL-positive isolates (99.5 %) were cefotaxime non-susceptible [CLSI or European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints)]. Fewer isolates (82 %) were ceftazidime non-susceptible (CLSI breakpoints). In addition, 21.1 % of E. coli, 25 % of K. oxytoca and 78.7 % of P. mirabilis isolates were ceftazidime susceptible but ESBL positive. This suggests that CLSI breakpoints for ceftazidime are too high to detect ESBLs. The lower EUCAST breakpoints detected ESBLs in E. coli and K. oxytoca better, but 59.6 % of ESBL-positive isolates of P. mirabilis were ceftazidime susceptible. For isolates with ertapenem MICs ≥0.5 µg ml(-1), more accurate ESBL phenotype analysis was observed for E. coli and K. pneumoniae (sensitivity >95 % for both, specificity 94.4 and 54.1 %, respectively). If carbapenemase-positive K. pneumoniae were excluded, the specificity increased to 78 %. The positive predictive values for the ESBL phenotypic test with E. coli and K. pneumoniae were 97.6 and 81.8 %, respectively, and negative predictive values were 75.9 and 95.2 %, respectively. We therefore suggest that it would be prudent to confirm phenotypic ESBL-positive P. mirabilis, K. pneumoniae and K. oxytoca with molecular analysis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24478449     DOI: 10.1099/jmm.0.068981-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  4 in total

1.  A locked nucleic acid (LNA)-based real-time PCR assay for the rapid detection of multiple bacterial antibiotic resistance genes directly from positive blood culture.

Authors:  Lingxiang Zhu; Dingxia Shen; Qiming Zhou; Zexia Li; Xiangdong Fang; Quan-Zhen Li
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

2.  Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia.

Authors:  Chen-Hsiang Lee; I-Ling Chen; Chia-Chin Li; Chun-Chih Chien
Journal:  Infect Drug Resist       Date:  2018-02-23       Impact factor: 4.003

3.  Population-based bloodstream infection surveillance in rural Thailand, 2007-2014.

Authors:  Julia Rhodes; Possawat Jorakate; Sirirat Makprasert; Ornuma Sangwichian; Anek Kaewpan; Thantapat Akarachotpong; Prasong Srisaengchai; Somsak Thamthitiwat; Supphachoke Khemla; Somkid Yuenprakhon; Wantana Paveenkittiporn; Anusak Kerdsin; Toni Whistler; Henry C Baggett; Christopher J Gregory
Journal:  BMC Public Health       Date:  2019-05-10       Impact factor: 3.295

4.  Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

Authors:  Pranita D Tamma; Virginia M Pierce; Sara E Cosgrove; Ebbing Lautenbach; Anthony Harris; Divya Rayapati; Jennifer H Han
Journal:  Open Forum Infect Dis       Date:  2018-06-08       Impact factor: 3.835

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.